- Home
- MU vs SNY Comparison
MU vs SNY Comparison
Compare MU & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MU
- SNY
- Stock Information
- Founded
- MU 1978
- SNY 1994
- Country
- MU United States
- SNY France
- Employees
- MU N/A
- SNY N/A
- Industry
- MU Semiconductors
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- MU Technology
- SNY Health Care
- Exchange
- MU Nasdaq
- SNY Nasdaq
- Market Cap
- MU 135.3B
- SNY 113.4B
- IPO Year
- MU N/A
- SNY N/A
- Fundamental
- Price
- MU $159.99
- SNY $46.97
- Analyst Decision
- MU Strong Buy
- SNY Buy
- Analyst Count
- MU 31
- SNY 4
- Target Price
- MU $160.29
- SNY $61.50
- AVG Volume (30 Days)
- MU 20.1M
- SNY 2.7M
- Earning Date
- MU 09-23-2025
- SNY 10-24-2025
- Dividend Yield
- MU 0.29%
- SNY 3.40%
- EPS Growth
- MU N/A
- SNY 118.56
- EPS
- MU 5.50
- SNY 8.65
- Revenue
- MU $33,813,000,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- MU $52.06
- SNY $1.53
- Revenue Next Year
- MU $32.32
- SNY $7.06
- P/E Ratio
- MU $29.08
- SNY $5.43
- Revenue Growth
- MU 58.22
- SNY 15.65
- 52 Week Low
- MU $61.54
- SNY $44.73
- 52 Week High
- MU $160.49
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- MU 83.39
- SNY 43.02
- Support Level
- MU $114.25
- SNY $46.50
- Resistance Level
- MU $160.34
- SNY $47.69
- Average True Range (ATR)
- MU 4.72
- SNY 0.68
- MACD
- MU 3.71
- SNY -0.18
- Stochastic Oscillator
- MU 98.71
- SNY 36.14
About MU Micron Technology Inc.
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.